Fibrobiologics Inc
FBLG0.259USD
-0.002-0.92%
收盤 12/19, 16:00（美東）報價延遲15分鐘
12.48M總市值
虧損本益比TTM
關於 Fibrobiologics Inc 公司
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Fibrobiologics Inc簡介
公司代碼FBLG
公司名稱Fibrobiologics Inc
上市日期Jan 31, 2024
CEOO'Heeron (Pete)
員工數量13
證券類型Ordinary Share
年結日Jan 31
公司地址455 E. Medical Center Blvd
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編77598
電話12816715150
網址https://fibrobiologics.com/
公司代碼FBLG
上市日期Jan 31, 2024
CEOO'Heeron (Pete)
Fibrobiologics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月14日 週日
更新時間: 12月14日 週日
持股股東
股東類型
持股股東
持股股東
佔比
O'Heeron (Peter)
8.88%
Golden Knight Inc LP
8.53%
The Vanguard Group, Inc.
1.85%
Yorkville Advisors Global, LP.
0.77%
Millennium Management LLC
0.67%
其他
79.30%
持股股東
持股股東
佔比
O'Heeron (Peter)
8.88%
Golden Knight Inc LP
8.53%
The Vanguard Group, Inc.
1.85%
Yorkville Advisors Global, LP.
0.77%
Millennium Management LLC
0.67%
其他
79.30%
股東類型
持股股東
佔比
Individual Investor
9.32%
Corporation
8.53%
Investment Advisor
4.70%
Hedge Fund
1.71%
Investment Advisor/Hedge Fund
1.45%
Research Firm
0.25%
Family Office
0.01%
其他
74.01%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
125
5.16M
16.27%
--
2025Q3
125
5.16M
16.27%
+26.14K
2025Q2
124
5.13M
16.68%
-1.32M
2025Q1
115
6.45M
16.82%
+104.96K
2024Q4
107
5.96M
16.68%
+467.89K
2024Q3
99
5.49M
10.74%
+2.00M
2024Q2
74
3.47M
1.58%
+2.95M
2024Q1
20
483.30K
0.00%
+483.30K
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
O'Heeron (Peter)
5.91M
14.1%
--
--
Apr 21, 2025
Golden Knight Inc LP
2.13M
5.1%
+9.85K
+0.46%
Apr 21, 2025
The Vanguard Group, Inc.
1.23M
2.95%
-186.64K
-13.14%
Jun 30, 2025
Millennium Management LLC
480.64K
1.15%
+480.64K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
715.58K
1.71%
-916.88K
-56.17%
Jun 30, 2025
Cascade Financial Partners, LLC
290.58K
0.69%
+30.50K
+11.73%
Jun 30, 2025
Geode Capital Management, L.L.C.
288.95K
0.69%
-325.69K
-52.99%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Proshares Ultra Russell 2000
佔比0%
Texas Capital Texas Small Cap Equity Index ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Fibrobiologics Inc的前五大股東是誰？
Fibrobiologics Inc的前五大股東如下：
O'Heeron (Peter)持有股份：5.91M佔總股份比例：14.10%。
Golden Knight Inc LP持有股份：2.13M佔總股份比例：5.10%。
The Vanguard Group, Inc.持有股份：1.23M佔總股份比例：2.95%。
Millennium Management LLC持有股份：480.64K佔總股份比例：1.15%。
BlackRock Institutional Trust Company, N.A.持有股份：715.58K佔總股份比例：1.71%。
O'Heeron (Peter)持有股份：5.91M佔總股份比例：14.10%。
Golden Knight Inc LP持有股份：2.13M佔總股份比例：5.10%。
The Vanguard Group, Inc.持有股份：1.23M佔總股份比例：2.95%。
Millennium Management LLC持有股份：480.64K佔總股份比例：1.15%。
BlackRock Institutional Trust Company, N.A.持有股份：715.58K佔總股份比例：1.71%。
Fibrobiologics Inc的前三大股東類型是什麼？
Fibrobiologics Inc 的前三大股東類型分別是：
O'Heeron (Peter)
Golden Knight Inc LP
The Vanguard Group, Inc.
O'Heeron (Peter)
Golden Knight Inc LP
The Vanguard Group, Inc.
有多少機構持有Fibrobiologics Inc(FBLG)的股份？
截至2025Q4，共有125家機構持有Fibrobiologics Inc的股份，合計持有的股份價值約為5.16M，占公司總股份的16.27% 。與2025Q3相比，機構持股有所增加，增幅為--。
哪個業務部門對Fibrobiologics Inc的收入貢獻最大？
在--，--業務部門對Fibrobiologics Inc的收入貢獻最大，創收--，占總收入的--% 。
